RG7356 / Roche - LARVOL DELTA

CD44v6 engages in colorectal cancer progression. (PubMed, Cell Death Dis) - "Moreover, clinical trials aiming to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and toxicity of a commercialized anti-CD44 monoclonal antibody developed by Roche (RO5429083) have been conducted among patients with CD44-expressing malignant tumors, and a clinical trial focusing on the dose escalation of this antibody is ongoing. Thus, we are hopeful that anti-CD44 therapy will be applied in the treatment of colorectal cancer in the future."

Journal • Review

TARGETING VIRUS ENV AND CD44 IMPROVES bNAb AVIDITY AND NEUTRALIZATION POTENCY (CROI 2019) - "Similar enhancement of virus neutralization was observed when PGDM1400 was replaced by other bnAbs (e.g., 10-074 and N6). Our data provide strong evidence that bnAbs neutralize most HIV-1 strains through predominantly monovalent binding and increasing avidity via binding to a host protein on the virion surface could substantially enhance virus neutralization."